WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

Alterations in ATC/DDD

List of new DDDs decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDDs will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD.

 

Change in ATC codes

INN/generic namePrevious ATC codeNew ATC codeDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
argipressinH01BA06H01BA01 2)Final2018
asunaprevirJ05AE15J05AP06Final2018
benzydamine A01AD02R02AX03 3)Final2018
boceprevirJ05AE12J05AP03Final2018
ceftriaxone, combinationsJ01DD54J01DD63 4)Final2018
daclatasvirJ05AX14J05AP07Final2018
dasabuvir, ombitasvir, paritaprevir and ritonavirJ05AX66J05AP52Final2018
dasabuvirJ05AX16J05AP09Final2018
elbasvir and grazoprevirJ05AX68J05AP54Final2018
faldaprevirJ05AE13J05AP04Final2018
ombitasvir, paritaprevir and ritonavirJ05AX67J05AP53Final2018
ribavirinJ05AB04J05AP01Final2018
simeprevir J05AE14J05AP05Final2018
sofosbuvir and ledipasvirJ05AX65J05AP51Final2018
sofosbuvirJ05AX15J05AP08Final2018
telaprevirJ05AE11J05AP02Final2018
1) Final: indicates that the date for objection has expired
2) Altered ATC level name to vasopressin (argipressin)
3) Split of code. Alteration of ATC code includes only benzydamine lozenges
4) Split of code. Combinations of ceftriaxone and other substances remain in J01DD54 while combinations of ceftriaxone and beta-lactamase inhibitors are moved to J01DD63

Change of ATC level name

Previous nameNew ATC level nameATC codeDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
Bile acid preparationsBile acids and derivativesA05AAFinal2018
eptacog alfacoagulation factor VIIaB02BD0801.09.20172018
ampicillin and enzyme inhibitorampicillin and beta-lactamase inhibitorJ01CR01Final2018
amoxicillin and enzyme inhibitoramoxicillin and beta-lactamase inhibitorJ01CR02Final2018
ticarcillin and enzyme inhibitorticarcillin and beta-lactamase inhibitorJ01CR03Final2018
piperacillin and enzyme inhibitorpiperacillin and beta-lactamase inhibitorJ01CR05Final2018
cefotaxime, combinationscefotaxime and beta-lactamase inhibitorJ01DD51Final2018
ceftazidime, combinationsceftazidime and beta-lactamase inhibitorJ01DD52Final2018
cefoperazone, combinationscefoperazone and beta-lactamase inhibitorJ01DD62Final2018
imipenem and enzyme inhibitorimipenem and cilastatinJ01DH51Final2018
ceftolozane and enzyme inhibitorceftolozane and beta-lactamase inhibitorJ01DI54Final2018
1) Final: indicates that the date for objection has expired

Change of DDDs

ATC codeLevel namePrevious DDDNew DDDDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
A03AB02glycopyrronium bromide3 mg P0.3 mg P01.09.20172018
L04AC01daclizumab0.35 g P5 mg PFinal2018
1) Final: indicates that the date for objection has expired

Last updated: 2017-05-09